abstract |
The present invention provides novel compounds which are derived from CD154 but lack the intracellular domain. In particular, the present invention provides TMZ-CD154 and methods of treating diseases wherein the novel molecule TMZ-CD154 is used. In particular, TMZ-CD154 is used to modulate immune responses in patients with immune-related diseases such as cancer and infectious diseases. The present invention also relates to a method of activating cells in vitro with said TMZ-CD154, and then using said activated cells for therapeutic purposes or for diagnostic purposes. |